Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 388Endometrial Neoplasms 221Uterine Cervical Neoplasms 217Breast Neoplasms 115Fallopian Tube Neoplasms 105Colorectal Neoplasms 91Carcinoma, Non-Small-Cell Lung 83Neoplasms 70Pancreatic Neoplasms 63Stomach Neoplasms 57Neoplasm Metastasis 54Prostatic Neoplasms 52Lung Neoplasms 49Melanoma 46Carcinoma, Ovarian Epithelial 44Triple Negative Breast Neoplasms 41Squamous Cell Carcinoma of Head and Neck 37Esophageal Neoplasms 37Carcinoma, Renal Cell 37Colonic Neoplasms 33Urinary Bladder Neoplasms 31Peritoneal Neoplasms 30Uterine Neoplasms 29Head and Neck Neoplasms 29Carcinoma, Hepatocellular 28Vulvar Neoplasms 27Small Cell Lung Carcinoma 25Carcinoma, Transitional Cell 25Uterine Cervical Dysplasia 22Sarcoma 19

Interventions

1-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Platinum-resistant Ovarian Cancer × Gynecologic × 90 days × Clear all
NCT05551507 2026-05-04

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

InxMed (Shanghai) Co., Ltd.

Phase 1/2 Recruiting
150 enrolled
Gynecologic

Platinum-resistant Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡